bioAffinity Technologies (BIAF) EBT (2021 - 2026)

bioAffinity Technologies has disclosed EBT across 6 years of filings, most recently posting -$3.6 million for Q1 2026.

• In Q1 2026, EBT fell 36.92% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$15.8 million (down 62.98% YoY), while the FY2025 annual figure was -$14.9 million, down 64.66% from the prior year.
• EBT fell to -$3.6 million in Q1 2026, from -$3.1 million in the prior quarter.
• Over the last five years, EBT for BIAF reached as high as -$88052.0 in Q2 2022 and fell as low as -$5.0 million in Q3 2025.
• The 5-year median for EBT is -$2.3 million (2023), against an average of -$2.6 million.
• Annual changes were most pronounced in 2022 — EBT soared 69.97% — and 2023, when it sank 1871.09%.
• A 5-year view of EBT shows it stood at -$1.7 million in 2022, then sank by 41.58% to -$2.4 million in 2023, then slipped by 25.14% to -$3.0 million in 2024, then dropped by 5.64% to -$3.1 million in 2025, then slipped by 15.84% to -$3.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$3.6 million, -$3.1 million, and -$5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.